TGTX // TG Therapeutics Inc.

DES <GO> NASDAQ CIK 0001001316 ↗

Health Care • Biotechnology: Pharmaceutical Preparations

$58.08 ▲ +0.68 (+1.19%)

MKT CAP: $8.89B • VOL: 1.79M

52W L $27 52W H $62

ALTMAN Z

12.92 SAFE

PIOTROSKI

6 / 9

TGTX // ROARABLE RATING & 5-PILLAR RQD CONFIDENCE 02:00 EST DETERMINISTIC ENGINE

PRIOR: RQD 61/100 [C-] (-1 PT) • UNCHANGED AS OF 2026-11-01

ROARABLE C-

RQD CONFIDENCE

60 / 100 -1D

5 X 20-PT QUANT PILLARS

E 0 D 35 C 59 B 70 A 86+

Roarable Hold — Cautious Neutral

01 MASSIVE / SEC XBRL

Forensic Fundamentals

[LOCKED] FLAGGED

UNLOCK BELOW TO REVEAL

02 OPRA GEX + SEC 13F

Whale & Options Flow

10 / 20

NEUTRAL

NET GEX +0% • CALL SWEEP 52% • P/C 0.65

03 SEC FORM 4 (90D)

Insider Conviction

[LOCKED] FLAGGED

UNLOCK BELOW TO REVEAL

04 FRED 90D r-MATRIX

Macro Regime Fit

13 / 20

SOLID

TAILWIND • r(10Y)=+0.00 (+23bp) • r(OAS)=+0.00

05 10-K REDLINE AUDIT

Forensic 10-K Risk

16 / 20

STRONG

20 BASE - 4 DEDUCT • 0 CRIT / 0 MED • STABLE

ALERT

Why did TGTX's Forensic Fundamentals & Insider Conviction sub-score just flash a warning? Enter your email to unlock the full 5-Pillar Rating Breakdown + get instant alerts whenever TGTX is Upgraded or Downgraded.

SIG <GO> CROSS-FEED TRIANGULATION // PROPRIETARY ANOMALY ENGINE (1 ACTIVE ON TGTX)

STAGE 2 DETERMINISTIC Z-SCORE + STAGE 3 GEEK DESK BRIEF ALL MARKET ANOMALIES <SIG>

▼ BEARISH // F-RATED EARNINGS MIRAGE // ACCRUAL WATCHSIFTER 02 // ACCRUAL & RECEIVABLES FORENSICS

SEVERITY: 89/100 Z-SCORE: +3.03σ

TGTX Accounting Gap: Net Income (+220%) Outpaced OCF (+38.9%) With +-44.6% Working-Capital Build

CASH CONVERSION GAP

+181.1% (NI vs OCF)

RECEIVABLES / WC BLOAT

-44.6% VS REV

60D C-SUITE FORM 4 SALES

0 OPEN-MKT DUMPS

[GEEK DESK FORENSIC NOTE // SEC XBRL × FORM 4 CROSS-CHECK]

SEC EDGAR XBRL CompanyFacts10-K/10-Q Working Capital ScheduleSEC Form 4 Executive Sales

SEC EDGAR XBRL triangulation on TG Therapeutics Inc. (TGTX) exposes a +181.1% Cash Conversion Gap as YoY Net Income growth (+220.0%) diverged from Operating Cash Flow growth (+38.9%). Non-cash current assets and receivables expanded -44.6% relative to top-line revenue growth. Monitor upcoming 10-Q cash realization closely for accrual mean-reversion.

TGTX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +81.11%▲ RESISTANCE BREAKOUT

2026-10-30O $58.15H $61.76L $58.00C $61.18VOL 2.85M

RES: $59.92SUP: $52.40SMA50: $55.33SMA200: $43.81

TGTX // INSTITUTIONAL BULL VS. BEAR FORENSIC DEBATE

HIGH-CONVICTION LONG CONVICTION: 88/100

BEAR 0

100 BULL

TG Therapeutics Inc. (TGTX) exhibits 83.7% gross margins and 12.0% return on invested capital within Health Care (Biotechnology: Pharmaceutical Preparations), balanced against a 73.3x enterprise multiple and 6.5% implied options volatility.

▲ INSTITUTIONAL BULL THESIS (LONG)

01. Operating Leverage & Capital Efficiency Moat

Sustained 83.7% gross profitability converts into 20.0% operating margin and 12.0% ROIC, outpacing sector cost of capital.

ROIC: 12.0% // GM: 83.7%

02. Top-Line Expansion & Cash Conversion

YoY revenue trajectory of +87.3% paired with -0.28% free cash flow yield supports self-funded R&D and capital return.

REV YOY: +87.3% // FCF YLD: -0.28%

03. Balance Sheet Solvency & Forensic Quality

Altman Z-Score of 12.92 and Piotroski F-Score of 6/9 indicate low near-term refinancing stress.

ALTMAN Z: 12.92 // F-SCORE: 6/9

▼ INSTITUTIONAL BEAR THESIS (SHORT / RISK)

01. Multiple Compression & Duration Sensitivity

Trading at 19.9x trailing P/E (16.7x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.

P/E: 19.9x // EV/EBITDA: 73.3x

02. Options Skew & Event Volatility Risk

Options market prices a ±6.5% implied move with a 0.65 put/call ratio around $57.00 max pain.

IMPL MOVE: ±6.5% // P/C: 0.65

03. Competitive Margin & CapEx Cycle Pressure

Elevated industry capital intensity and customer concentration in Biotechnology: Pharmaceutical Preparations require continuous execution to defend 68.0% net margins.

NET MARGIN: 68.0% // D/E: 0.38x

KEY CATALYST // Upcoming 10-Q/10-K XBRL margin progression, guidance revision vs 16.7x forward consensus, and institutional 13F positioning.

MACRO REGIME // Monitor US 10Y Real Yields (DFII10) and High-Yield Credit Spreads (OAS) for beta-adjusted multiple impact (Beta 0.87).

FORM 4 & 13F FLOW OPEN OWN <GO>

FILER	SIDE	$ VALUE
INSPECT FULL OWNERSHIP LEDGER IN OWN <GO>

UNUSUAL OPTIONS TAPE OPEN OPT <GO>

STRIKE / EXP	TYPE	PREMIUM
INSPECT GEX & CHAIN IN OPT <GO>

KEY VALUATION & PROFITABILITY RATIOS XBRL FA <GO>

TRAILING P/E 19.9x

FORWARD P/E 16.7x

EV / EBITDA 73.3x

FCF YIELD -0.28%

GROSS MARGIN 83.7%

OPERATING MARGIN 20.0%

NET MARGIN 68.0%

ROIC % 12.0%

REV GROWTH YOY +87.3%

DILUTED EPS TTM $2.92

DEBT / EQUITY 0.38x

DIVIDEND YIELD 0.00%

RSI-14 MOMENTUM 69.7

5Y EQUITY BETA 0.87

FRED MACRO SENSITIVITY (PEARSON r) ECST <GO>

MACRO CORRELATION CALIBRATION ACTIVE BELOW.

FRED MACRO REGIME STRESS-TEST SIMULATOR // TGTXPEARSON R VARIANCE ENGINE

01 // SELECT FEDERAL RESERVE & CREDIT SHOCK SCENARIO

02 // POSITION NOTIONAL EXPOSURE

HEADLINE STRESS SCORE

75/100SEVERE DRAWDOWN PRESSURE

PRIMARY FACTOR EXPOSURE

DFII10 // -0.61 r

Latest: 2.08%

EST. DIRECTIONAL MOVE

-8.50%

Implied Px: $53.15

EST. DOLLAR VARIANCE

-$4,248

On $50,000 Notional

[LOCKED // MULTI-FACTOR DRAWDOWN HEDGE & MACRO TRIGGER ALERT]

Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for TGTX & activate live FRED threshold breach alerts.

HEAD-TO-HEAD PEER COMPARISONS COMP <GO>

TGTX VS LLY

MARGINS ROIC VALUATION

TGTX VS JNJ

MARGINS ROIC VALUATION

TGTX VS ABBV

MARGINS ROIC VALUATION

TGTX VS UNH

MARGINS ROIC VALUATION